In a report published Friday, Citigroup analyst Yaron Werber reiterated a Buy rating on Celgene Corporation CELG, and raised the price target from $182.00 to $204.00.
In the report, Citigroup noted, “We conducted a detailed analysis and our key takeaway is that Revlimid/dex is set to dominate the myeloma market over the long-term. We are raising our Revlimid and Pomalyst ests and believe that this tailwind is much greater than appreciated over the long-term. Celgene has a deep myeloma pipeline with 3 promising novel early stage drugs that should further sustain its dominance. As Celgene's financial guidance is looking very outdated, it will likely be raised in Jan. Our new $222 TP is based on 27x '14 EPS $7.54 vs consensus $7.29.”
Celgene Corporation closed on Thursday at $164.51.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in